MRI detection of brain gadolinium retention in multiple sclerosis: Magnetization transfer vs. T1‐weighted imaging

Abstract

AbstractBackground and PurposeEvidence of brain gadolinium retention has affected gadolinium‐based contrast agent usage. It is, however, unclear to what extent macrocyclic agents are retained and whether their in vivo detection may necessitate nonconventional MRI. Magnetization transfer (MT) could prove suitable to detect gadolinium‐related signal changes since dechelated gadolinium ions bind to macromolecules. Therefore, this study aimed to investigate associations of prior gadolinium administrations with MT and T1 signal abnormalities.MethodsA cohort of 23 persons with multiple sclerosis (MS) (18 females, 5 males, 57 ± 8.0 years) with multiple past gadolinium administrations (median 6, range 3‐12) and 23 age‐ and sex‐matched healthy controls underwent 1.5 Tesla MRI with MT, T1‐weighted 2‐dimensional spin echo, and T1‐weighted 3‐dimensional gradient echo. The signal intensity index was assessed by MRI in gadolinium retention predilection sites.ResultsThere were dose‐dependent associations of the globus pallidus signal on gradient echo (r = .55, p < .001) and spin echo (r = .38, p = .013) T1‐weighted imaging, but not on MT. Relative to controls, MS patients had higher signal intensity index in the dentate nucleus on T1‐weighted gradient echo (1.037 ± 0.040 vs. 1.016 ± 0.023, p = .04) with a similar trend in the globus pallidus on T1‐weighted spin echo (1.091 ± 0.034 vs. 1.076 ± 0.014, p = .06). MT detected no group differences.ConclusionsConventional T1‐weighted imaging provided dose‐dependent associations with gadolinium administrations in MS, while these could not be detected with 2‐dimensional MT. Future studies could explore newer MT techniques like 3D and inhomogenous MT. Notably, these associations were identified with conventional MRI even though most patients had not received gadolinium administrations in the preceding 9 years, suggestive of long‐term retention.